Top

Published in:

01-06-2013 | Research Article

Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis

Authors: Ze-Kun Zhao, Wen-Guang Wu, Lei Chen, Ping Dong, Jun Gu, Jia-Sheng Mu, Jia-Hua Yang, Ying-Bin Liu

Published in: Tumor Biology | Issue 3/2013

Abstract

The aim of this current study was to investigate the clinicopathologic features and prognostic significance of UbcH10 in pancreatic ductal adenocarcinoma (PDA). Real-time quantitative RT-PCR was employed to examine UbcH10 expression in 20 pairs of PDA and adjacent non-cancerous tissues. In addition, UbcH10 expression was analyzed by immunohistochemistry in 94 clinicopathologically characterized PDA cases. The correlation of UbcH10 expression with patients’ survival rate was assessed by Kaplan–Meier and Cox regression. Our results showed that the expression levels of UbcH10 mRNA and protein in PDA tissues were both significantly higher than those in non-cancerous tissues. Simultaneously, high expression of UbcH10 was significantly correlated with the clinical stage (p < 0.001), degree of histological differentiation (p < 0.001), and lymph node metastasis (p = 0.001). Moreover, high expression of UbcH10 was significantly associated with poor overall survival in PDA patients. In conclusion, UbcH10 might play a positive role in tumor development and could serve as an independent predictor of poor prognosis for PDA.

Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Zali MR, Pourhoseingholi MA. Pancreatic cancer mortality and misclassification—bayesian analysis. Asian Pac J Cancer Prev. 2011;12:2271–4.PubMed

Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43–9. doi:10.1016/j.surg.2012.05.020.PubMedCrossRef

Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22. doi:10.1002/jso.23192.PubMedCrossRef

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003;63:4167–73.PubMed

Berlingieri MT, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A, et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 2007;43:2729–35.PubMedCrossRef

Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2007;26:2136–40. doi:10.1038/sj.onc.1210010.PubMedCrossRef

Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005;93:464–71. doi:10.1038/sj.bjc.6602721.PubMedCrossRef

Lin J, Raoof DA, Wang Z, Lin MY, Thomas DG, Greenson JK, et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia. 2006;8:1062–71.PubMedCrossRef

Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, Del Vecchio L, et al. UbcH10 expression in human lymphomas. Histopathology. 2009;54:731–40. doi:10.1111/j.1365-2559.2009.03296.x.PubMedCrossRef

10.

Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H. Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 2009;9:87.PubMedCrossRef

11.

Chen SM, Jiang CY, Wu JY, Liu B, Chen YJ, Hu CJ, et al. RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clin Exp Pharmacol Physiol. 2010;37:525–9.PubMedCrossRef

12.

Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 2011;30:2405–19. doi:10.1038/emboj.2011.154.PubMedCrossRef

13.

Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007;121:33–8. doi:10.1002/ijc.22605.PubMedCrossRef

14.

van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 2010;188:83–100. doi:10.1083/jcb.200906147.PubMedCrossRef

15.

Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004;23:6621–9. doi:10.1038/sj.onc.1207861.PubMedCrossRef

16.

Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.

17.

Piperi C, Vlastos F, Farmaki E, Martinet N, Papavassiliou AG. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med. 2008;12:1495–501. doi:10.1111/j.1582-4934.2008.00309.x.PubMedCrossRef

18.

Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–28. doi:10.2353/ajpath.2009.080874.PubMedCrossRef

19.

Yang S. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 2007;8:829–33. doi:10.1038/nrg2218.CrossRef

20.

Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer. 2008;123:1–7. doi:10.1002/ijc.23605.PubMedCrossRef

Title: Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis
Authors: Ze-Kun Zhao
Wen-Guang Wu
Lei Chen
Ping Dong
Jun Gu
Jia-Sheng Mu
Jia-Hua Yang
Ying-Bin Liu
Publication date: 01-06-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0671-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA

Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma

GSTT1 null genotype contributes to increased risk of gastric cancer in Chinese population: evidence from a meta-analysis

Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir

Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation

RETRACTED ARTICLE: Association of GSTT1 gene polymorphisms with the risk of prostate cancer: an updating meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer